Literature DB >> 33105176

Valproic Acid in the Treatment of Migraines.

Brandy L Brown1, Lauren K Craycraft, Stephanie Baker Justice.   

Abstract

Migraine headaches can be a disabling condition for patients. Fortunately, most patients can be successfully managed in the outpatient setting, however, there are a number of patients who may not respond to the abortive treatments that they have been prescribed. These patients often present to the emergency department (ED) for further assistance with the management of their condition. Migraines are the fourth most common cause of ED visits and are associated with an estimated annual cost of $17 billion in the United States. Familiarity with abortive treatments is critical for providers in the ED as are treatments, such as valproic acid, that may be considered in patients who do not respond to other treatment options. Many providers are more familiar with the role of valproic acid in the treatment of mood and seizure disorders, but its tolerability and the successes reported in the primary literature make it a reasonable consideration for patients with migraine who fail to respond to other therapies. This article briefly summarizes the therapies considered first line for abortive treatment in the setting of migraines and provides an overview of the primary literature describing the use of valproic acid in these patients.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33105176     DOI: 10.1097/TME.0000000000000319

Source DB:  PubMed          Journal:  Adv Emerg Nurs J        ISSN: 1931-4485


  2 in total

Review 1.  A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.

Authors:  Nazir Noor; Alexis Angelette; Abby Lawson; Anjana Patel; Ivan Urits; Omar Viswanath; Cyrus Yazdi; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-06-28

Review 2.  Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update.

Authors:  Laura Giuseppina Di Pasqua; Marta Cagna; Clarissa Berardo; Mariapia Vairetti; Andrea Ferrigno
Journal:  Biomedicines       Date:  2022-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.